Anatara Lifesciences Ltd

ASX:ANR ISIN:AU000000ANR0

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Following the successful licencing of our first product to leading global animal health company, Zoetis Inc, we are now focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

     

Latest Headlines

Anatara Lifesciences Ltd (ASX:ANR) Video Interview with CEO Steven Lydeamore on Development of Human Health Product

🕔3/22/2019 1:03:12 PM

Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore, recently appointed to the company, is interviewed by ABN Newswire on the development of Irritable Bowl Syndrome (IBS) dietary supplements to address the growing need for a product that addresses the full range of IBS symptoms.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report

🕔3/19/2019 9:29:24 AM

PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Pitt Street Research Report

🕔3/19/2019 9:13:38 AM

Pitt Street Research has released its latest initiating research and valuation report on Anatara Lifesciences (ASX:ANR). The report provides a $1.34 per share base case and a $3.61 optimistic case using a probability-weighted DCF valuation approach.

Read Full Article

News

Anatara Lifesciences Ltd (ASX:ANR) Video Interview with CEO Steven Lydeamore on Development of Human Health Product

🕔3/22/2019 1:03:12 PM

Anatara Lifesciences Ltd (ASX:ANR) CEO Steven Lydeamore, recently appointed to the company, is interviewed by ABN Newswire on the development of Irritable Bowl Syndrome (IBS) dietary supplements to address the growing need for a product that addresses the full range of IBS symptoms.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report

🕔3/19/2019 9:29:24 AM

PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Pitt Street Research Report

🕔3/19/2019 9:13:38 AM

Pitt Street Research has released its latest initiating research and valuation report on Anatara Lifesciences (ASX:ANR). The report provides a $1.34 per share base case and a $3.61 optimistic case using a probability-weighted DCF valuation approach.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Half Yearly Report

🕔2/19/2019 8:21:30 AM 990

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4D financial report for the half year ending 31st December 2018.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Investor Presentation

🕔2/19/2019 8:20:45 AM 930

Anatara Lifesciences (ASX:ANR) is pleased to release a copy of the presentation that Chief Executive Officer, Mr Steven Lydeamore, will be presenting at the Proactive Investors Australia CEO Sessions and the Wholesale Investor's Emergence 2019 conferences this month.

Read Full Article

Anatara Life Sciences (ASX:ANR) Investor Presentations Sydney and Melbourne

🕔2/11/2019 1:13:00 PM 1388

This month, Anatara's CEO, Steve Lydeamore will be presenting to investors at events in Sydney and Melbourne. We would like to extend to you the invitation to attend.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Successful proof of concept studies

🕔2/7/2019 11:23:57 AM 1522

Anatara Lifesciences Ltd (ASX:ANR) is pleased to report positive efficacy data from its in vitro Proof of Concept studies of its Gastrointestinal ReProgramming product. GaRP is a unique natural dietary supplement designed to restore and maintain a healthy human gut and microbiome.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report

🕔1/30/2019 11:03:48 AM 1352

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 31st December 2018. The Company's cash position at the end of the quarter stood at $1.5m. The Company also had $4,500,000 in deposits with terms of greater than 90 days. Expenditure during the quarter was in line with forecast.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) Non-Executive Director Appointment

🕔1/23/2019 8:21:56 AM 1714

Anatara Lifesciences (ASX:ANR) is pleased to announce the appointment of Dr. David Brookes as Non-Executive Director and Chair of the Audit and Risk Committee, effective from 23 January 2019.

Read Full Article

Anatara Lifesciences Ltd (ASX:ANR) PAC Partners Equity Research Report

🕔1/15/2019 12:31:24 PM 1652

PAC Partners Equity Research has released its latest research and valuation report on Anatara Lifesciences (ASX:ANR). The report provided a BUY rating and a 12-month price target of $1.40 per share.

Read Full Article
###

31,370 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 128) (Last 30 Days: 1310) (Since Published: 31370) 

Markets ASX:ANR

Company Data

    Headquarters
  • 433 Logan Road, Stones Corner
    Brisbane, Queensland 4120
    Australia
  • Principal Sector
  • Biotech 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.anataralifesciences.com
  • E:
  • info@anataralifesciences.com

Company Reports

Presentations

Research Report

Quarterly Report

Social Media